Trials / Unknown
UnknownNCT03457844
A Study of Anlotinib in Patients With Gastroenteropancreatic Neuroendocrine Tumor G3
A Single Group, Open Label, Multi-center Clinical Trial to Assess the Efficacy and Safety of Anlotinib in Patients With Gastroenteropancreatic Neuroendocrine Tumor G3
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
To assess the primary effects and safety of Anlotinib in patients with Gastroenteropancreatic Neuroendocrine Tumor G3.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Anlotinib | Anlotinib is followed Day 1 to day 14 by 7 days off treatment in a 21-day cycle） and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent |
Timeline
- Start date
- 2018-01-30
- Primary completion
- 2019-08-30
- Completion
- 2019-08-30
- First posted
- 2018-03-08
- Last updated
- 2018-09-11
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03457844. Inclusion in this directory is not an endorsement.